V Fonseca

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. doi request reprint New developments in diabetes management: medications of the 21st century
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana Electronic address
    Clin Ther 36:477-84. 2014
  2. pmc Determinants of weight gain in the action to control cardiovascular risk in diabetes trial
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 36:2162-8. 2013
  3. doi request reprint Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Ther 35:714-23. 2013
  4. doi request reprint Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Diabetes Complications 27:268-73. 2013
  5. doi request reprint Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Med 126:141-9. 2013
  6. doi request reprint Saxagliptin overview: special focus on safety and adverse effects
    Shamsa Ali
    Tulane University, Medicine, New Orleans 70112, USA
    Expert Opin Drug Saf 12:103-9. 2013
  7. doi request reprint Overview of metformin: special focus on metformin extended release
    Shamsa Ali
    Tulane University, New Orleans 70112, USA
    Expert Opin Pharmacother 13:1797-805. 2012
  8. pmc Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
    Vivian A Fonseca
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 35:1225-31. 2012
  9. doi request reprint Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
    V Fonseca
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetes Obes Metab 14:365-71. 2012
  10. pmc Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA
    Health Qual Life Outcomes 8:99. 2010

Detail Information

Publications102 found, 100 shown here

  1. doi request reprint New developments in diabetes management: medications of the 21st century
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana Electronic address
    Clin Ther 36:477-84. 2014
    ..Suboptimal blood glucose control among patients with type 2 diabetes continues to support the need for new pharmacologic approaches...
  2. pmc Determinants of weight gain in the action to control cardiovascular risk in diabetes trial
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 36:2162-8. 2013
    ..Identify determinants of weight gain in people with type 2 diabetes mellitus (T2DM) allocated to intensive versus standard glycemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial...
  3. doi request reprint Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Ther 35:714-23. 2013
    ..The purpose of this review is to highlight some of the novel approaches that are being developed to improve glucose control in patients with diabetes...
  4. doi request reprint Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Diabetes Complications 27:268-73. 2013
    ..This novel selective inhibitor of sodium glucose co-transporter 2 is in clinical development for the treatment of patients with type 2 diabetes mellitus (T2DM)...
  5. doi request reprint Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Med 126:141-9. 2013
    ..To determine whether a combination of L-methylfolate, methylcobalamin, and pyridoxal-5'-phosphate (LMF-MC-PLP [Metanx; Pamlab LLC, Covington, La]) improves sensory neuropathy...
  6. doi request reprint Saxagliptin overview: special focus on safety and adverse effects
    Shamsa Ali
    Tulane University, Medicine, New Orleans 70112, USA
    Expert Opin Drug Saf 12:103-9. 2013
    ..Saxagliptin can be used safely in renal failure (with dose adjustment) and in hepatic impairment. When saxagliptin is used in combination with a strong inhibitor of CYP3A4/A5, reduction in the daily dosage is recommended...
  7. doi request reprint Overview of metformin: special focus on metformin extended release
    Shamsa Ali
    Tulane University, New Orleans 70112, USA
    Expert Opin Pharmacother 13:1797-805. 2012
    ..Results of UKPDS, one of the largest and longest studies, showed reductions in cardiovascular mortality in patients using metformin...
  8. pmc Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
    Vivian A Fonseca
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 35:1225-31. 2012
    ..To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes...
  9. doi request reprint Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
    V Fonseca
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetes Obes Metab 14:365-71. 2012
    ..To investigate whether patients taking metformin for type 2 diabetes mellitus (T2DM) have improved glycaemic control without compromising tolerability by adding an agent with a complementary mechanism of action vs. uptitrating metformin...
  10. pmc Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA
    Health Qual Life Outcomes 8:99. 2010
    ..This meta-analysis examined the correlations of two measurements of medication adherence: MEMS and SRQs...
  11. pmc Bile acid sequestrants for lipid and glucose control
    Bart Staels
    Institut Pasteur de Lille, 1 rue Calmette BP245, 59019, Lille Cedex, France
    Curr Diab Rep 10:70-7. 2010
    ....
  12. pmc Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
    Lizheng Shi
    School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, New Orleans, LA 70112, USA
    BMC Psychiatry 9:80. 2009
    ..To examine the baseline metabolic monitoring (MetMon) for second generation antipsychotics (SGA) among patients with schizophrenia in the Veterans Integrated Service Network (VISN) 16 of the Veterans Health Administration (VHA)...
  13. ncbi request reprint Identification and treatment of prediabetes to prevent progression to type 2 diabetes
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Cornerstone 8:10-8; discussion 19-20. 2007
    ..An A1C level > or =7% should signal the need to initiate or change therapy to achieve glycemic goals...
  14. doi request reprint Management of type 2 diabetes: oral agents, insulin, and injectables
    Vivian A Fonseca
    Tulane University Medical Center, New Orleans, LA 70112 2699, USA
    J Am Diet Assoc 108:S29-33. 2008
    ..Newer agents and insulins have become available since the UK Prospective Diabetes Study was completed and have enhanced our armamentarium of therapeutics for treatment of diabetes...
  15. ncbi request reprint The effects of insulin on the endothelium
    Vivian A Fonseca
    Tullis Tulane Alumni Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Endocrinol Metab Clin North Am 36:20-6. 2007
    ..Doses of insulin adequate to restore normoglycemia may help overcome these abnormalities, although some patients may require insulin sensitization with lifestyle changes or pharmacologic therapy...
  16. doi request reprint Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Horm Metab Res 40:427-30. 2008
  17. ncbi request reprint Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus
    Vivian A Fonseca
    Department of Medicine and Pharmacology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Am J Med 120:S18-25. 2007
    ..Insulin-sensitizing therapy with TZDs is a promising intervention for patients with diabetes at risk for adverse cardiovascular outcomes...
  18. ncbi request reprint Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Cornerstone 8:S7-18. 2007
    ..Pharmacologic therapies that are currently in development may help not only to promote weight loss but also to improve the symptoms of cardiometabolic risk in patients with and without diabetes...
  19. ncbi request reprint Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
    ..To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]...
  20. ncbi request reprint Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetologia 50:1148-55. 2007
    ..This study assessed the efficacy and tolerability of vildagliptin added to insulin therapy in patients with type 2 diabetes...
  21. ncbi request reprint Commentary: Of HOPEs and DREAMs: the quest to prevent type 2 diabetes
    Vivian A Fonseca
    Tulane University Medical Center, 1430 Tulane Avenue, SL 53, New Orleans, Louisiana 70112 2699, USA
    J Clin Endocrinol Metab 91:4762-3. 2006
  22. ncbi request reprint Commentary: the PROactive study--the glass is half full
    Vivian Fonseca
    Tulane University Medical Center, New Orleans, Louisiana 70112, USA
    J Clin Endocrinol Metab 91:25-7. 2006
  23. ncbi request reprint Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?
    Vivian Fonseca
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112 2699, USA
    Am J Cardiol 96:13M-18M. 2005
    ..This decreased responsiveness may be related to the severity of endothelial function in patients with diabetes. Additional therapeutic strategies may be needed to overcome this problem...
  24. ncbi request reprint Diabetes treatments have differential effects on nontraditional cardiovascular risk factors
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    J Diabetes Complications 20:14-20. 2006
    ..The aim of this study was to determine the effect of basal insulin, alone or with a sensitizer, or a combination of oral agents on nontraditional risk factors for cardiovascular disease (CVD)...
  25. ncbi request reprint The metabolic syndrome, hyperlipidemia, and insulin resistance
    Vivian A Fonseca
    Department of Medicine, Section of Endocrinology, Tulane University School of Medicine, New Orleans, Louisiana 70112 2699, USA
    Clin Cornerstone 7:61-72. 2005
    ..Several promising pharmacologic interventions that may have an important role in the management of metabolic syndrome by treating adipose tissue-mediated metabolic disturbances are in the early stages of development...
  26. ncbi request reprint Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease
    Vivian A Fonseca
    Diabetes Program, Tulane University Medical Center, New Orleans, LA 70112 2699, USA
    J Clin Hypertens (Greenwich) 8:713-20; quiz 721-2. 2006
    ..Clinical trials now under way will further evaluate the role of renin-angiotensin system inhibition in preventing diabetes and its microvascular and macrovascular complications...
  27. ncbi request reprint Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials
    V Fonseca
    Section of Endocrinology and Metabolism, Tulane University Health Sciences Centre, 1430 Tulane Avenue SL 53, New Orleans, LA 70112, USA
    Diabetologia 47:1914-23. 2004
    ....
  28. doi request reprint Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca
    Vivian A Fonseca
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Am J Med 124:S54-61. 2011
    ..Accordingly, incretin-based agents have an advantage because they are unlikely to cause hypoglycemia...
  29. pmc An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
    V Fonseca
    Department of Endocrinology, Tulane University Medical Center, New Orleans, LA 70112, USA
    Diabetes Obes Metab 13:814-22. 2011
    ..To evaluate the benefits of initiating insulin at an earlier versus later treatment stage, and regimens with/without sulfonylurea (SU)...
  30. doi request reprint Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus
    Vivian A Fonseca
    Section of Endocrinology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Am J Cardiol 108:52B-8B. 2011
    ..This article provides a summary of these ongoing trials, and discusses the impact of glycemic control and strategies to promote CV risk reduction in patients with diabetes...
  31. ncbi request reprint Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus
    Vivian Fonseca
    Tulane University Health Sciences Center, 1430 Tulane Avenue SL 53, New Orleans, LA 70112, USA
    Curr Med Res Opin 19:635-41. 2003
    ..Thus, all aspects of glucose metabolism appear to be clinically relevant and should be monitored for effective diabetes management. Further study will more precisely define the clinical significance of PPG...
  32. doi request reprint Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Curr Med Res Opin 26:1621-8. 2010
    ..This analysis aimed to determine if measurable clinical characteristics prior to starting insulin could predict differences in improved glycemic control between these options...
  33. pmc Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
    Vivian A Fonseca
    Tulane University Health Sciences Center in New Orleans, New Orleans, LA 70112, USA
    Diabetes Obes Metab 12:384-92. 2010
    ..This review examines data from three phase III clinical trials that evaluated the glucose- and lipid-lowering effects of colesevelam when added to the existing antidiabetes treatment regimen of patients with T2DM...
  34. doi request reprint Effects of beta-blockers on glucose and lipid metabolism
    Vivian A Fonseca
    Tulane University School of Medicine, New Orleans, LA, USA
    Curr Med Res Opin 26:615-29. 2010
    ..Despite these clinical benefits, many physicians are reluctant to prescribe beta-blockers because of perceived negative metabolic effects, including reduced glycemic control, masking of hypoglycemia, insulin resistance, and dyslipidemia...
  35. ncbi request reprint A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study
    Vivian Fonseca
    Tulane University, 430 Tulane Avenue SL53, New Orleans, LA 70112, USA
    Am J Med Sci 328:274-80. 2004
    ....
  36. ncbi request reprint Identification and treatment of prediabetes to prevent progression to type 2 diabetes
    Vivian A Fonseca
    Professor of Medicine and Pharmacology, Tullis Tulane Alumni Chair in Diabetes, Section of Endocrinology, Tulane University Health Sciences Center, 1430 Tulane Avenue SL 53, New Orleans, LA 70112, USA
    Clin Cornerstone 9:51-9; discussion 60-1. 2008
    ..An A1C level > or = 7% should signal the need to initiate or change therapy to achieve glycemic goals...
  37. pmc Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences
    Vivian A Fonseca
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Diabetes Care 32:1632-8. 2009
    ..To examine the impact of Hurricane Katrina on the health of individuals with diabetes...
  38. pmc Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy
    Vivian A Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 31:1479-84. 2008
    ..This study tested the LDL cholesterol-lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy...
  39. ncbi request reprint beta-blocker use and diabetes symptom score: results from the GEMINI study
    J B McGill
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Diabetes Obes Metab 9:408-17. 2007
    ..In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms...
  40. ncbi request reprint Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial
    V Fonseca
    Department of Medicine, Tulane University, New Orleans, LA 70112, USA
    JAMA 283:1695-702. 2000
    ....
  41. doi request reprint Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  42. ncbi request reprint Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients
    V Fonseca
    Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112, USA
    Diabetes Care 23:354-9. 2000
    ..To determine the long-term effects of troglitazone as monotherapy or in combination with sulfonylureas or insulin regarding glycemic and lipid measures...
  43. ncbi request reprint Effect of thiazolidinediones on body weight in patients with diabetes mellitus
    Vivian Fonseca
    Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112 2699, USA
    Am J Med 115:42S-48S. 2003
    ..Further research is needed to define the optimal dietary modifications that can be used universally in TZD-treated patients to minimize weight gain while effectively treating insulin resistance and hyperglycemia...
  44. doi request reprint Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials
    L A Bazzano
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112 2715, USA
    Diabet Med 25:924-32. 2008
    ..We systematically analysed evidence from randomized controlled trials (RCTs) examining the safety and efficacy of neutral protamine Hagedorn (NPH) insulin and glargine in the management of adults with Type 2 diabetes...
  45. ncbi request reprint Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control
    Vivian Fonseca
    Tulane University Medical Center, New Orleans, Louisiana, USA
    Diabetes Care 26:1685-90. 2003
    ..To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic control and on postprandial glucose and insulin levels in patients with type 2 diabetes...
  46. ncbi request reprint Management of the insulin resistance syndrome
    C Desouza
    Tulane University Health Sciences Center, Department of Medicine, Section of Endocrinology SL53, 1430 Tulane Avenue, New Orleans, LA 70112-2699, USA
    Curr Diab Rep 1:140-7. 2001
    ..Optimal treatment will not only improve glycemic control, but may also significantly lower cardiovascular disease...
  47. ncbi request reprint The metabolic syndrome and chronic kidney disease in U.S. adults
    Jing Chen
    Tulane University Schools of Medicine and Public Health and Tropical Medicine, New Orleans, Louisiana 70112, USA
    Ann Intern Med 140:167-74. 2004
    ..The metabolic syndrome is a common risk factor for cardiovascular disease...
  48. doi request reprint Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes
    A Toprani
    Department of Family and Community Medicine Section of Preventive Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
    Diabetes Obes Metab 13:276-80. 2011
    ..The use of TZDs in clinical practice has the potential to increase morbidity and health care costs. The purpose of this study was to compare the incidence of CHF in TZD and non-TZD-treated patients in a clinical setting...
  49. ncbi request reprint Effect of intensive treatment on vascular and other complications of diabetes mellitus
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Cornerstone 6:40-50. 2004
    ....
  50. ncbi request reprint Management of diabetes in the hospital
    Vivian Fonseca
    Department of Medicine and Pharmacology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 7:S10-7. 2006
    ....
  51. ncbi request reprint Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy
    A Jawa
    Department of Medicine, Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana 70112 2699, USA
    J Clin Endocrinol Metab 91:31-5. 2006
    ..African-Americans are reported to respond less well to ACEI and are at increased risk of disease progression...
  52. ncbi request reprint Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES
    Paul Muntner
    Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA
    Ann Epidemiol 14:686-95. 2004
    ..To calculate the prevalence of non-traditional cardiovascular disease (CVD) risk factors across diabetes status and for persons with and without the metabolic syndrome...
  53. ncbi request reprint The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy
    Rubin Zhang
    Tulane Abdominal Transplant Institute, Tulane University Health Sciences Center, New Orleans, LA, USA
    Clin Transplant 21:583-9. 2007
    ..8%, 80.6%, 71.4%, and 58.8% respectively. There was a low incidence of rejection and CMV infection. Basiliximab induction with TAC, MFA, and steroid maintenance therapy can provide excellent long-term outcome for SPK recipients...
  54. doi request reprint Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome
    Lizheng Shi
    Tulane University and Southeast Louisiana Veterans Health Care System, New Orleans, LA 70112, USA
    Curr Med Res Opin 26:2499-506. 2010
    ..To assess the association between pre-existing metabolic syndrome and health outcomes among veterans with schizophrenia...
  55. pmc Case-based study: from prediabetes to complications--opportunities for prevention
    Jonathan Rappaport
    Section of Endocrinology, Diabetes and Metabolism, Tulane University Health Sciences Center, Veterans Affairs Medical Center, New Orleans, Louisiana, USA
    PLoS Med 2:e40. 2005
  56. ncbi request reprint Effects of the thiazolidinediones on cardiovascular risk factors
    Lucia Gilling
    Section of Endocrinology, Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112, USA
    Am J Cardiovasc Drugs 2:149-56. 2002
    ..Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events...
  57. pmc Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion
    Tina K Thethi
    Tulane University Health Sciences, New Orleans, LA, USA
    J Diabetes Complications 24:73-8. 2010
    ..To systematically investigate the effect of lack of adherence to the recommended change in insulin pump infusion line use beyond 48 h and determine whether the type of insulin made a difference...
  58. ncbi request reprint Relationship between HbA1c level and peripheral arterial disease
    Paul Muntner
    Department of Epidemiology, Tulane University SPHTM, 1430 Tulane Ave, SL 18 New Orleans, LA 70112, USA
    Diabetes Care 28:1981-7. 2005
    ..We sought to evaluate the association of HbA(1c) (A1C) with peripheral arterial disease in a representative sample of the U.S. population with and without diabetes...
  59. pmc Physician practice behavior and practice guidelines: using unannounced standardized patients to gather data
    N Kevin Krane
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112 2699, USA
    J Gen Intern Med 24:53-6. 2009
    ..Measuring actual practice behaviors of physicians, particularly as they relate to established clinical guidelines, is challenging. Standardized patients provide one method of collecting such data...
  60. ncbi request reprint Cardiovascular effects of insulin sensitizers in diabetes
    Ali Jawa
    Department of Medicine and Pharmacology, Tulane University Medical Center, New Orleans, LA 70112, USA
    Curr Opin Investig Drugs 7:806-14. 2006
    ..Ongoing clinical trials are underway investigating the role of thiazolidinediones in the prevention of type 2 diabetes mellitus...
  61. ncbi request reprint The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats
    Vivian Fonseca
    Department of Medicine, Section of Endocrinology, Tulane University School of Medicine, New Orleans LA 70112 2699, USA
    Metabolism 51:783-6. 2002
    ..These data support the hypothesis that insulin may regulate homocysteine metabolism through regulation of hepatic C beta S activity, although activity of other hepatic enzymes not studied here may also contribute to these observations...
  62. ncbi request reprint Insulin resistance and risk of chronic kidney disease in nondiabetic US adults
    Jing Chen
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    J Am Soc Nephrol 14:469-77. 2003
    ..Further studies into the causality between insulin resistance and CKD are warranted...
  63. doi request reprint Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices
    Lizheng Shi
    Tulane University, New Orleans, Louisiana, USA
    Pharmacoeconomics 28:1097-107. 2010
    ..A majority of them showed high or moderate correlation with medication adherence measured using monitoring devices, and could be considered for measuring patient-reported adherence prospectively...
  64. ncbi request reprint Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring
    Cyrus Desouza
    Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 26:1485-9. 2003
    ....
  65. doi request reprint Urinary catalytic iron in obesity
    Tina K Thethi
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Clin Chem 57:272-8. 2011
    ..Catalytic iron, which has been associated with these chronic diseases, may be one of the links between obesity and these multifactorial diverse disorders...
  66. ncbi request reprint Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients
    Brandy Panunti
    Department of Medicine, Tulane University Health Sciences Center, and Department of Medicine, Veterans Affairs Medical Center, New Orleans, LA 70112, United States
    Vascul Pharmacol 45:29-35. 2006
    ....
  67. ncbi request reprint Metabolic syndrome and heart failure
    Tina Thethi
    Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Heart Fail Clin 2:1-11. 2006
  68. ncbi request reprint The impact of antidiabetic therapies on cardiovascular disease
    Brandy Panunti
    Department of Medicine, Section of Endocrinology, Tulane University Medical Center, New Orleans, LA 70112 2699, USA
    Curr Atheroscler Rep 7:50-7. 2005
    ..In contrast, insulin secretagogues have very little effect on both cardiovascular risk factors and outcomes...
  69. ncbi request reprint Differential association of birth weight with cardiovascular risk variables in African-Americans and Whites: the Bogalusa heart study
    Fawaz Mzayek
    Tulane Center for Cardiovascular Health and Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Ann Epidemiol 14:258-64. 2004
    ..To study the relationship between low birth weight and the subsequent development of cardiovascular risk factors and to compare this relationship between African-Americans and whites at 7 to 21 years of age...
  70. ncbi request reprint A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy
    R Zhang
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
    Am J Transplant 7:1815-21. 2007
    ..AA may not have worse long-term outcomes than CA recipients of SPK with basiliximab induction and tacrolimus (TAC), mycophenolate acid (MFA) and steroid maintenance immunotherapy...
  71. ncbi request reprint Nontraditional risk factors for cardiovascular disease in diabetes
    V Fonseca
    Section of Endocrinology, Department of Medicine, Tulane University Medical Center, New Orleans, Louisiana 70112, USA
    Endocr Rev 25:153-75. 2004
    ..We will also discuss the impact of various therapies used in patients with diabetes on nontraditional risk factors...
  72. ncbi request reprint Newly diagnosed diabetes/hyperglycemia in hospitals: what should we do?
    Vivian Fonseca
    Department of Medicine Section of Endocrinology and the Department of Surgery, Tulane University Health Sciences Center, New Orleans, Louisiana and the Veterans Affairs Medical Center, New Orleans, Louisiana
    Endocr Pract 12:108-11. 2006
    ..To examine the clinical problem of newly diagnosed diabetes/hyperglycemia in hospitals, and to develop a management strategy...
  73. ncbi request reprint Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet
    Sunil Asnani
    Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans 70112 2699, USA
    Curr Med Res Opin 19:609-13. 2003
    ..Weight gain is a frequent side-effect of thiazolidinediones, possibly related to fluid retention and stimulation of pre-adipocyte differentiation...
  74. ncbi request reprint Single-composition extended-release metformin hydrochloride. A viewpoint by Vivian Fonseca
    Vivian Fonseca
    Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Treat Endocrinol 3:333-4. 2004
  75. pmc The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster
    Roberta McDuffie
    Tulane University Medical Center, New Orleans, LA, USA
    Contemp Clin Trials 29:756-61. 2008
    ..We describe the actions taken and the relative success/failure of such actions...
  76. ncbi request reprint Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  77. pmc Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats
    Subramanyam N Murthy
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Diabetes 59:3240-6. 2010
    ..However, the effect of salsalate on vascular injury has not been determined. The objective of this study is to investigate the effect of salsalate on vascular injury and repair in a rat model of carotid artery balloon catheter injury...
  78. ncbi request reprint Drugs affecting homocysteine metabolism: impact on cardiovascular risk
    Cyrus Desouza
    Tulane University School of Medicine, New Orleans, USA
    Drugs 62:605-16. 2002
    ....
  79. ncbi request reprint Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California San Francisco Medical Education Program, Fresno, 93703, USA
    Am J Med 118:939-47. 2005
    ..Three clinical trials are being conducted to test whether early pharmacotherapy can reduce or delay the incidence of diabetes, and their results may well begin to shift the treatment paradigm toward earlier intervention...
  80. ncbi request reprint Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects
    Vivian A Fonseca
    Section of Endocrinology, Tulane University Health Sciences Center, New Orleans VA Hospital, LA, USA
    Atherosclerosis 167:105-9. 2003
    ..To determine whether plasma homocysteine (tHcy) levels were related to insulin resistance and obesity in subjects without diabetes or vascular disease...
  81. ncbi request reprint Effects of thiazolidinediones on cardiovascular risk factors
    Biswanath P Gouda
    Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA, USA
    Compr Ther 28:200-6. 2002
    ..These drugs can potentially decrease the risk of cardiovascular disease by correcting the different components of the insulin resistance syndrome...
  82. ncbi request reprint The role of iron in diabetes and its complications
    Sundararaman Swaminathan
    Division of Nephrology, University of Arkansas for Medical Sciences, 4301 West Markham St, Slot 501, Little Rock, AR 72205, USA
    Diabetes Care 30:1926-33. 2007
  83. ncbi request reprint Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis
    Pierre Theuma
    Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, SL 53, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Diab Rep 3:248-54. 2003
    ....
  84. ncbi request reprint Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    Denise E Bonds
    Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA
    Am J Cardiol 99:80i-89i. 2007
    ..In addition, translation of the principles behind the monitoring of severe hypoglycemia in ACCORD into feasible strategies for use in clinical practice will be needed...
  85. ncbi request reprint Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes
    Cyrus Desouza
    Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Diabetes Care 25:1336-9. 2002
    ..Its effects on endothelial function in these patients have not been previously assessed...
  86. doi request reprint Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
    Ronald B Goldberg
    Lipid Disorders Clinic, Division of Endocrinology Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Arch Intern Med 168:1531-40. 2008
    ..Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus. Achieving glycemic control safely with insulin therapy can be challenging...
  87. ncbi request reprint Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents
    Mark C Granberry
    Pharmacy Program, College of Health Sciences and Human Services, University of Texas Pan American, Edinburg, Texas 78539, USA
    Am J Cardiovasc Drugs 5:201-9. 2005
    ..Data on the effects of the alpha-glucosidase inhibitors and insulin secretagogs are sparse; however, these drugs appear to have little or no effect on cardiovascular risk factors...
  88. ncbi request reprint Potential cardiovascular benefits of insulin sensitizers
    Biju P Kunhiraman
    Section of Endocrinology, Diabetes, and Metabolism, Tulane University and Hospital, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Endocrinol Metab Clin North Am 34:117-35. 2005
    ..Several clinical trials that were designed to investigate the effect that these agents have on reducing cardiovascular events are well under way...
  89. ncbi request reprint Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease
    Vivian A Fonseca
    Department of Medicine, and Pharmacology, Tulane University Health Sciences Center, New Orleans, Lousiana 70112, USA
    Am J Cardiol 92:50J-60J. 2003
    ..Long-term clinical trials are being conducted to determine the effect that thiazolidinediones have on cardiovascular events in individuals with type 2 diabetes...
  90. ncbi request reprint Diabetic nephropathy and retinopathy
    Ali Jawa
    Section of Endocrinology, Department of Medicine, Tulane University Health Sciences Center, SL 53, 1430 Tulane Avenue, New Orleans, LA 70112 2699, USA
    Med Clin North Am 88:1001-36, xi. 2004
    ..Because nephropathy and retinopathy are frequently linked in patients,this article reviews their common and individual aspects of pathophysiology, clinical features, and management...
  91. pmc Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies
    Ajay D Rao
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Diabetes Care 31:1672-8. 2008
    ..We therefore evaluated the effects of combination therapy of sulfonylureas and metformin on the risk of all-cause mortality and cardiovascular disease (CVD) among people with type 2 diabetes...
  92. ncbi request reprint Erectile dysfunction: interrelationship with the metabolic syndrome
    Glenn Matfin
    Global Clinical Research, Novartis Pharmaceuticals, One Health Plaza, East Hanover, NJ 07936 1080, USA
    Curr Diab Rep 5:64-9. 2005
    ....
  93. ncbi request reprint Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes
    Ali A Jawa
    Department of Medicine, Section of Endocrinology, Tulane University Medical Center, SL 53, 1430 Tulane Avenue, New Orleans, LA 70112 2699, USA
    Cardiol Clin 23:119-38. 2005
    ..Thus, further prospective studies in this area are necessary...
  94. ncbi request reprint Insulin resistance syndrome
    Vivian A Fonseca
    Endocr Pract 9:567-9; author reply 569. 2003
  95. ncbi request reprint Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats
    Cyrus V Desouza
    Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Cardiovasc Pharmacol Ther 8:297-305. 2003
    ..We studied the effect of fenofibrate and rosiglitazone on intimal hyperplasia in the Zucker rat, a model for insulin resistance and type 2 diabetes mellitus, following balloon catheter-induced injury...
  96. ncbi request reprint Insulin therapy in type 2 diabetes. Introduction
    Vivian A Fonseca
    Clin Cornerstone 8:8-9. 2007
  97. ncbi request reprint The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin
    David S H Bell
    Endocr Pract 13:808-9. 2007
  98. ncbi request reprint The insulin resistance syndrome and coronary artery disease
    David M Kendall
    International Diabetes Center, Park Nicollet Clinic, 3800 Park Nicollet Blvd, St Louis Park, MN 55416, USA
    Coron Artery Dis 14:335-48. 2003
    ..A proposed approach to the management of patients with the insulin resistance syndrome is discussed...
  99. ncbi request reprint Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet
    Subramanyam N Murthy
    Section of Endocrinology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Metabolism 54:645-52. 2005
    ..These findings may have important implications for the prevention of cardiovascular disease and events in patients with hyperhomocysteinemia (HHcy)...
  100. ncbi request reprint A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit
    Natalie K Schiller
    Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Mol Cell Biochem 240:31-7. 2002
    ..This inhibition may be due in part to decreased VSMC proliferation, which may be a function of enhanced endothelial regrowth, but not the return of endothelium-dependent vascular function...
  101. ncbi request reprint Oxidants in chronic kidney disease
    Sudhir V Shah
    University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 501, Little Rock, AR 72205, USA
    J Am Soc Nephrol 18:16-28. 2007
    ..It concludes by reviewing the limited human data that provide some proof of concept that the observations in experimental models may be relevant to human disease...